Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report), retaining the price target of $30.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Evan Seigerman has given his Buy rating due to a combination of factors that highlight Pfizer’s strategic positioning in the breast cancer treatment market. The company’s focus on developing atirmociclib as a first-line treatment for HR+/HER2- breast cancer patients is a significant move, aiming to capture a substantial portion of this patient demographic. Atirmociclib’s favorable safety profile, with lower rates of severe neutropenia compared to other treatments, positions it as a potentially superior option for patients.
Additionally, Pfizer’s pipeline includes promising investigational treatments such as KAT6, CDK2, and vepdegestrant, which could enhance their offerings in the second-line and beyond settings. The strong response rates and progression-free survival data from these agents, particularly KAT6, underscore their potential. Furthermore, Pfizer’s recent acquisitions and strategic investments, funded by COVID-related revenue, are expected to drive top-line growth and margin expansion, making the stock undervalued compared to its peers in the U.S. BioPharma sector.
In another report released on June 4, Jefferies also reiterated a Buy rating on the stock with a $33.00 price target.
PFE’s price has also changed slightly for the past six months – from $25.370 to $24.840, which is a -2.09% drop .